Reducing Cognitive Impairment by Management of Heart Failure as a Modifiable Risk Factor

Recruiting N/A Interventional Study
Heart Failure Cognitive Impairment Dementia Left Ventricular Dysfunction Cognitive Change Cognitive Decline
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Prevention
Participants needed
168 (estimated)
Sponsor
Baker Heart and Diabetes Institute · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This study will test the feasibility and effectiveness of an innovative model of care for cognitively impaired patients with heart failure. This program aims to improve cognition, reduce dementia risk and cardiovascular events, and will be supported by innovative digital technology for wide scale rollout and implementation. Findings from this research will transform the way healthcare is delivered…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Hospitalised with HF as primary or secondary diagnosis. 2. At least mild cognitive impairment (CI) based on Montreal Cognitive Assessment (MoCA) on hospital discharge. Exclusion Criteria: 1. Unable to provide written consent; requiring palliative care; or participating in a…
Contacts

Quan Huynh

610385321833

quan.huynh@baker.edu.au

CONTACT